Get started
Author

Marissa Chen

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
2017 · Filippo Pietrantonio, Federica Di Nicolantonio, et al. · JNCI Journal of the National Cancer Institute · 324
PDF
Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2019 · Yumi Yokoyama, Erin D. Lew, et al. · Cancer Research · 92
Identification of a differentiation stall in epithelial mesenchymal transition in histone H3–mutant diffuse midline glioma
2020 · Lauren M Sanders, Allison Cheney, et al. · GigaScience · 14
PDF
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF V600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study.
2024 · Reinhard Dummer, Mitchell Levesque, et al. · Journal of Clinical Oncology · 2
PDF
Missing the Malignancy in Primary Care: A Case Study on Pediatric Osteosarcoma
2025 · Marissa Chen, Neesha Ramchandani · Journal of Pediatric Health Care · 1
Negative symptom dimensions link cognitive impairment to global and social functioning in 22q11.2 deletion syndrome
2026 · David A. Parker, Marissa Chen, et al. · Schizophrenia Research
PDF
Abstract A012: Emergence of MEK1 mutations in RAF or RAS-mutant solid tumors following treatment with a combination of selective type II RAF inhibitor belvarafenib and MEK inhibitor cobimetinib
2024 · Stephanie Hilz, Marissa Chen, et al. · Cancer Research
Data from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2023 · Yumi Yokoyama, Erin D. Lew, et al.
Supplementary Data from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2023 · Yumi Yokoyama, Erin D. Lew, et al.
Supplementary Table S5 from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2023 · Yumi Yokoyama, Erin D. Lew, et al.
Supplementary Table S6 from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2023 · Yumi Yokoyama, Erin D. Lew, et al.
Supplementary Table S6 from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2023 · Yumi Yokoyama, Erin D. Lew, et al.
Data from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2023 · Yumi Yokoyama, Erin D. Lew, et al.
Abstract 5274: A novel, statistical-based method to determine RNA expression by next-generation sequencing in clinical FFPE samples
2016 · Robert Shoemaker, Aaron Berlin, et al. · Cancer Research
Works count: 14
Citation count: 433
H-index: 3
I10-index: 3
Year
Topic
Type